...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of surgical oncology >Fluorescence-guided surgery with a fluorophore-conjugated antibody to carcinoembryonic antigen (CEA), that highlights the tumor, improves surgical resection and increases survival in orthotopic mouse models of human pancreatic cancer
【24h】

Fluorescence-guided surgery with a fluorophore-conjugated antibody to carcinoembryonic antigen (CEA), that highlights the tumor, improves surgical resection and increases survival in orthotopic mouse models of human pancreatic cancer

机译：用荧光团结合的抗癌胚抗原（CEA）抗体进行荧光引导的手术，突出了肿瘤，改善了手术切除率，并提高了人胰腺癌原位小鼠模型的存活率

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. We have developed a method of distinguishing normal tissue from pancreatic cancer in vivo using fluorophore-conjugated antibody to carcinoembryonic antigen (CEA). The objective of this study was to evaluate whether fluorescence-guided surgery (FGS) with a fluorophore-conjugated antibody to CEA, to highlight the tumor, can improve surgical resection and increase disease-free survival (DFS) and overall survival (OS) in orthotopic mouse models of human pancreatic cancer. Methods. We established nude-mouse models of human pancreatic cancer with surgical orthotopic implantation of the human BxPC-3 pancreatic cancer. Orthotopic tumors were allowed to develop for 2 weeks. Mice then underwent bright-light surgery (BLS) or FGS 24 h after intravenous injection of anti-CEA-Alexa Fluor 488. Completeness of resection was assessed from postoperative imaging. Mice were followed postoperatively until premorbid to determine DFS and OS. Results. Complete resection was achieved in 92 % of mice in the FGS group compared to 45.5 % in the BLS group (p = 0.001). FGS resulted in a smaller postoperative tumor burden (p = 0.01). Cure rates with FGS compared to BLS improved from 4.5 to 40 %, respectively (p = 0.01), and 1-year postoperative survival rates increased from 0 % with BLS to 28 % with FGS (p = 0.01). Median DFS increased from 5 weeks with BLS to 11 weeks with FGS (p = 0.0003). Median OS increased from 13.5 weeks with BLS to 22 weeks with FGS (p = 0.001). Conclusions. FGS resulted in greater cure rates and longer DFS and OS using a fluorophore-conjugated anti-CEA antibody. FGS has potential to improve the surgical treatment of pancreatic cancer.
机译：背景。我们已经开发出一种使用抗癌胚抗原（CEA）的荧光团偶联抗体在体内区分正常组织和胰腺癌的方法。这项研究的目的是评估荧光诱导的手术（FGS）与CEA的荧光团结合抗体，以突出肿瘤，可以改善手术切除率并增加无病生存期（DFS）和总生存期（OS）。人类胰腺癌的原位小鼠模型。方法。我们建立了人类BxPC-3胰腺癌的手术原位植入人类胰腺癌的裸鼠模型。原位肿瘤被允许发展2周。静脉注射抗CEA-Alexa Fluor 488后24小时，对小鼠进行强光手术（BLS）或FGS。根据术后影像学评估切除的完整性。术后对小鼠进行随访，直至病情确定DFS和OS。结果。 FGS组中92％的小鼠达到了完全切除，而BLS组中为45.5％（p = 0.001）。 FGS导致较小的术后肿瘤负担（p = 0.01）。与BLS相比，FGS的治愈率分别从4.5％提高到40％（p = 0.01），术后1年生存率从BLS的0％提高到FGS的28％（p = 0.01）。中位DFS从BLS的5周增加到FGS的11周（p = 0.0003）。中位OS从BLS的13.5周增加到FGS的22周（p = 0.001）。结论使用荧光团偶联的抗CEA抗体，FGS可以提高治愈率，延长DFS和OS。 FGS具有改善胰腺癌外科治疗的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号